Source link : https://www.newshealth.biz/health-news/doac-monotherapy-bests-dual-antithrombotic-therapy-for-afib-plus-coronary-disease/
LONDON — For patients with atrial fibrillation (Afib) and stable coronary artery disease (CAD), edoxaban (Savaysa) monotherapy improved net outcomes weighing together bleeding and ischemic events as compared with dual antithrombotic therapy, the EPIC-CAD trial showed. The 12-month composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, or major bleeding […]
Author : News Health
Publish date : 2024-09-01 19:47:25
Copyright for syndicated content belongs to the linked Source.
Categories